Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway Inhibitors-Reference-Cited by-同舟云学术

Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway Inhibitors

Published:2024 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Yoshida Yuya¹²,Takahashi Masanobu¹²,Komine Keigo²,Taniguchi Sakura²,Yamada Hideharu²,Sasaki Keiju²,Umegaki Sho²,Kawamura Yoshifumi²,Kasahara Yuki²³,Ouchi Kota²,Imai Hiroo²,Saijo Ken²,Shirota Hidekazu²,Takenaga Noriko²,Ishioka Chikashi¹²

Affiliation:

1. Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Japan

2. Department of Medical Oncology, Tohoku University Hospital, Japan

3. Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan

Publisher

Japanese Society of Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_3373-23/_pdf

Reference28 articles.

1. 1. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96: 1788-1795, 2007.

2. 2. Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell 176: 1248-1264, 2019.

3. 3. Alexandre J, Cautela J, Ederhy S, et al. Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc 9: e018403, 2020.

4. 4. Van Leeuwen MT, Luu S, Gurney H, et al. Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews. JNCI Cancer Spectr 4: pkaa076, 2020.

5. 5. Ueda T, Uemura H, Tomita Y, et al. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol 43: 616-628, 2013.